Many CDMOs have taken actions to meet the growing demand of viral vector development and manufacturing services for clinical trials, as well as for commercial scale production. While capacity is important, there are only a few companies who provide services across the entire supply and value chain. So, what should you expect when choosing a true one-stop-shop as a CDMO partner in the gene therapy space?
Fully digital partnering at BIO-Europe Spring 2020
Sponsored PublicationsBIO-Europe Spring: Leading life sciences partnering event pivots to deliver dealmaking
opportunities in a new format during very unusual times. With just 16 days to plan, EBD Group transformed BIO-Europe Spring from a physical event held in Paris to a fully digital solution where 1,700 delegates around the world participated in virtual partnering meetings and panels.
Life in a bubble – droplet science
BackgroundIts a discovery that revolutionises our fundamental understanding of cells. Tiny droplets called condensates that form through weak interactions between proteins and RNA are at the heart of many key biological processes. Dewpoint Therapeutics – the first start-up to harness the basic research for a new therapeutic platform technology – is now opening a facility in the German capital Berlin.
Nanolitre dispensing
ProductsThe acoustic dispensing technology of the Echo-Series Liquid Handlers has revolutionised the transfer of liquids.
Swiss biotech sector with robust growth
Latest NewsLast year, the biotechnology sector in Switzerland has continued its growth and proved to be a magnet for fresh capital and investment. This is revealed by the Swiss Biotech Report 2020.
Viral vector one-stop-shop for gene and cell therapy
Sponsored PublicationsMany CDMOs have taken actions to meet the growing demand of viral vector development and manufacturing services for clinical trials, as well as for commercial scale production. While capacity is important, there are only a few companies who provide services across the entire supply and value chain. So, what should you expect when choosing a true one-stop-shop as a CDMO partner in the gene therapy space?
Prepared for the time after COVID-19
AppointmentsMedicen Paris Region, the health innovation hub in Île-de-France, announces the appointment of Jessica Leygues as CEO.
COVID-19: Novartis starts study on hyped malaria drug
Latest NewsUp to today, Novartis and Bayer announced donations of several millions of old antimalaria pills based on anecdotical reports of efficacy in COVID-19 patients. Now Novartis has started a study.
Product hopping Boon or Bane?
OpinionIntellectual Property Providing access to medicines at affordable prices while maintaining incentives for the originators to invest into significant innovations is a balance that’s hard to find. Product hopping is a strategy for originators to minimise the erosion of their sales that has caught the attention of regulators and courts.
Product hopping – Boon or Bane?
OpinionIntellectual Property Providing access to medicines at affordable prices while maintaining incentives for the originators to invest into significant innovations is a balance that’s hard to find. Product hopping is a strategy for originators to minimise the erosion of their sales that has caught the attention of regulators and courts.
COVID 19: Halix ready for vaccine production
Latest NewsDutch Halix BV will manufacture a ChAdOx1 nCoV-19 vaccine, developed at the University of Oxford .